Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Amphiregulin as a monitoring biomarker during treatment of acute GvHD

Shernan Holtan, MD, University of Minnesota, Minneapolis, MN, comments on the potential of amphiregulin as a biomarker to monitor patients during treatment of acute graft-versus-host disease (GvHD). Using samples collected from two prospective clinical trials, it was found that amphiregulin levels decreased in patients responding to treatment. This biomarker could be useful in clinical practice to monitor patients and determine whether a patient’s symptoms are related to GvHD or not. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.